OTTAWA, Aug. 15 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," announced today that
Andrew Rae has resigned as a director of Liponex in order to concentrate on
his responsibilities as President and CEO of iCo Therapeutics Inc. The Board
of Directors would like to thank Mr. Rae for his many contributions as a
director of the Company, including service on the Audit and Nomination and
Corporate Governance committees.
